ANTX
AN2 Therapeutics Inc

602
Mkt Cap
$143.76M
Volume
267,435.00
52W High
$6.91
52W Low
$1.00
PE Ratio
-3.44
ANTX Fundamentals
Price
$4.00
Prev Close
$3.91
Open
$3.76
50D MA
$1.92
Beta
0.72
Avg. Volume
75,664.67
EPS (Annual)
-$1.16
P/B
2.07
Rev/Employee
$0.00
$23.56
Loading...
Loading...
News
all
press releases
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry...
Business Wire·4d ago
News Placeholder
More News
News Placeholder
AN2 Therapeutics Stock Cools Off After 90% Rally
AN2 Therapeutics stock dips in premarket after a 90% surge tied to a $40 million equity raise.read more...
Benzinga·10d ago
News Placeholder
Power Hour Surge: Biotech Cash Floods, Energy Breakouts, and AI Bets Drive the Stocks to Watch into the Close
As Wall Street heads into the final stretch of the trading day, capital flows into biotech financing, clean energy, and emerging technology platforms are shaping the stocks traders are watching most closely into the close and after-hours session. $EONR, $SAFX, $KBLB, $HIMS, $MDCX, $ANTX, $NVO, $MDCX, $RLMD, $SLDB, $ANTX, $EDIT, $DDD
24-7 Market News·12d ago
News Placeholder
AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?
AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the company announced a $40 million private placement financing.read more...
Benzinga·12d ago
News Placeholder
ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally?
AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.
Stocktwits·12d ago
News Placeholder
AN2 Therapeutics Announces $40 Million Private Placement Financing
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has...
Business Wire·12d ago
News Placeholder
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to...
Business Wire·18d ago
News Placeholder
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder...
Business Wire·1mo ago
News Placeholder
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug...
Business Wire·2mo ago
News Placeholder
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·2mo ago
<
1
2
...
>

Latest ANTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.